ClinicalTrials.gg
CompletedNCT03974932Updated Mar 2, 2026Results posted

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

A Phase 3 interventional study of HTX-011 and Ibuprofen in Analgesia, sponsored by Heron Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
87th of 364
116 · median 70
Started
2019
with 34 others
Phase 3
42 of 364
2 open now
Registered
186th of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 87th largest by enrollment, is one of 35 that started in 2019, is one of 42 in phase 3, and was the 186th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.

03

Conditions studied

  • Analgesia

Browse trials for

Keywords

  • total knee arthroplasty
  • postoperative pain
  • multimodal analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo primary unilateral TKA under spinal anesthesia.
  • Has not previously undergone TKA in either knee.
  • Has an (ASA) Physical Status of I, II, or III.
  • Is able to walk at least 20 feet with optional use of a 4-legged walker for balance.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or is at least 2 years ; or is in a monogamous relationship with a partner who is surgically sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Has a planned concurrent surgical procedure.
  • Has other pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Using or expected to use Factor IX Complex or anti-inhibitor coagulant concentrates during the study.
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken NSAIDs within 10 days prior to the scheduled surgery with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
  • Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
  • Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half lives.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Is currently undergoing treatment for , , or .
  • Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
  • Has acquired defective color vision or acute gastrointestinal ulcers, either of which could interfere with scheduled study medications.
  • Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature.
  • Has any chronic condition or disease that would compromise neurological or vascular assessments.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a (BMI) >39 kg/m2.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Cohort 1

    HTX-011 + MMA

    Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Device: Luer Lock Applicator

  • Experimental
    Cohort 2

    HTX-011 + MMA

    Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Device: Luer Lock Applicator

  • Experimental
    Cohort 3

    HTX-011 + MMA

    Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Drug: +/- Bupivacaine HCl · Device: Luer Lock Applicator · Drug: HTX-011

  • Experimental
    Cohort 4

    HTX-011 + MMA

    Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Device: Luer Lock Applicator

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).

    The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

    Time frame: 12 through 48 hours

Secondary outcomes

  1. Mean AUC of VAS Scores.

    The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

    Time frame: 72 hours

  2. Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).

    Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.

    Time frame: 72 hours

  3. Percentage of Subjects With Severe Pain.

    Severe Pain defined as a VAS score ≥7.5 cm.

    Time frame: 24 hours, 48 hours, 72 hours

  4. Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).

    Time frame: 72 hours

  5. Percentage of Subjects Who Are Opioid-free

    Time frame: 72 Hours to Day 11

  6. Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.

    Time frame: 72 hours through Day 11

  7. Median Time to First Opioid Rescue Medication.

    Time frame: Through 72 hours

  8. Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.

    Time frame: 72 hours

  9. Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.

    Time frame: 72 hours through Day 11

  10. Percentage of Subjects Achieving a Score of "Good" or Better (>1) Pain Control Based on Patient Global Assessment (PGA).

    Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).

    Time frame: 24 hours, 48 hours, 72 hours, Day 11

  11. Median Time to First Ambulation Postsurgery.

    Time frame: 72 hours

  12. Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.

    Time frame: 72 hours

  13. Percentage of Subjects Who First Achieve an MPADSS Score ≥9.

    Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.

    Time frame: 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24, hours, 36 hours, 48 hours, 60 hours, 72 hours

  14. Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.

    Number Analyzed represents Subjects who were discharged home.

    Time frame: 72 hours

  15. Mean Overall Benefit of Analgesia Score (OBAS).

    Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.

    Time frame: 24 hours, 48 hours, 72 hours, Day 11

  16. Mean Total TSQM-9 Score

    The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.

    Time frame: 72 hours through Day 11

  17. Maximum Concentration (Cmax)

    Time frame: 72 hours

  18. Time of Occurrence of Maximum Concentration (Tmax)

    Time frame: 72 hours

07

Results

Posted Aug 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Started66141620
Completed66141620
Not completed0000

Outcome measures

PrimaryMean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).

The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

Time frame:
12 through 48 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).
pain intensity score*hrCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).155.57 ± 95.651185.27 ± 86.898161.36 ± 86.627126.59 ± 118.431
SecondaryMean AUC of VAS Scores.

The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

Time frame:
72 hours
Reported as:
Mean · pain intensity score*hr
Mean AUC of VAS Scores.
pain intensity score*hrCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Mean AUC of VAS Scores.277.03 ± 164.004319.81 ± 158.746276.87 ± 146.578216.18 ± 206.164
SecondaryMean AUC of the NRS of Pain Intensity at Rest (NRS-R).

Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.

Time frame:
72 hours
Reported as:
Mean · pain intensity score*hr
Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).
pain intensity score*hrCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).309.89 ± 155.289355.20 ± 161.377311.00 ± 136.714245.00 ± 200.369
SecondaryPercentage of Subjects With Severe Pain.

Severe Pain defined as a VAS score ≥7.5 cm.

Time frame:
24 hours, 48 hours, 72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects With Severe Pain.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
24 Hours26456
48 Hours29556
72 Hours23557
SecondaryMean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).
Time frame:
72 hours
Reported as:
Mean · MME, morphine milligram equivalency
Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).
MME, morphine milligram equivalencyCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).26.40 ± 23.22931.50 ± 24.90723.40 ± 14.48417.62 ± 22.167
SecondaryPercentage of Subjects Who Are Opioid-free
Time frame:
72 Hours to Day 11
Reported as:
Number · participants
Percentage of Subjects Who Are Opioid-free
participantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Who Are Opioid-free254310
SecondaryPercentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.
Time frame:
72 hours through Day 11
Reported as:
Count of participants · Participants
Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.9105
SecondaryMedian Time to First Opioid Rescue Medication.
Time frame:
Through 72 hours
Reported as:
Median · Hours
Median Time to First Opioid Rescue Medication.
HoursCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Median Time to First Opioid Rescue Medication.6.12 (4.27 to 8.25)5.63 (2.12 to 19.48)9.96 (4.18 to 15.90)12.76 (5.80 to 47.10)
SecondaryPercentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.
Time frame:
72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.4181213
SecondaryPercentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.
Time frame:
72 hours through Day 11
Reported as:
Count of participants · Participants
Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.448817
SecondaryPercentage of Subjects Achieving a Score of "Good" or Better (>1) Pain Control Based on Patient Global Assessment (PGA).

Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).

Time frame:
24 hours, 48 hours, 72 hours, Day 11
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving a Score of "Good" or Better (>1) Pain Control Based on Patient Global Assessment (PGA).
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
24 Hours60101416
48 Hours61111416
72 Hours66121518
Day 1150111115
SecondaryMedian Time to First Ambulation Postsurgery.
Time frame:
72 hours
Reported as:
Median · Hours
Median Time to First Ambulation Postsurgery.
HoursCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Median Time to First Ambulation Postsurgery.20.66 (18.48 to 23.43)23.20 (6.08 to 54.62)26.72 (24.37 to 29.60)20.58 (5.83 to 23.92)
SecondaryPercentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.
Time frame:
72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.23123
SecondaryPercentage of Subjects Who First Achieve an MPADSS Score ≥9.

Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.

Time frame:
2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24, hours, 36 hours, 48 hours, 60 hours, 72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects Who First Achieve an MPADSS Score ≥9.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Through 2 Hours15220
Through 4 Hours16323
Through 6 Hours21657
Through 8 Hours29688
Through 12 Hours38798
Through 24 Hours4581115
Through 36 Hours52121318
Through 48 Hours57121319
Through 60 Hours57121519
Through 72 Hours59131519
SecondaryPercentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.

Number Analyzed represents Subjects who were discharged home.

Time frame:
72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.
ParticipantsCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.61101620
SecondaryMean Overall Benefit of Analgesia Score (OBAS).

Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.

Time frame:
24 hours, 48 hours, 72 hours, Day 11
Reported as:
Mean · Scores on a scale
Mean Overall Benefit of Analgesia Score (OBAS).
Scores on a scaleCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
24 Hours6.5 ± 2.757.4 ± 6.367.6 ± 3.245.9 ± 3.45
48 Hours5.7 ± 2.764.9 ± 1.445.9 ± 2.895.3 ± 2.57
72 Hours5.1 ± 2.464.1 ± 1.774.9 ± 1.884.8 ± 2.29
Day 115.0 ± 2.435.2 ± 2.084.9 ± 2.084.9 ± 2.07
SecondaryMean Total TSQM-9 Score

The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.

Time frame:
72 hours through Day 11
Reported as:
Mean · Scores on a scale
Mean Total TSQM-9 Score
Scores on a scaleCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Global Satisfaction Domain - 72 Hours86.9 ± 15.5377.0 ± 22.6289.3 ± 14.7586.8 ± 13.57
Effectiveness Doman - 72 Hours86.4 ± 18.0980.2 ± 20.5284.0 ± 14.6181.9 ± 15.39
Convenience Domain - 72 Hours90.1 ± 12.0384.5 ± 17.1893.1 ± 13.0786.9 ± 16.45
Global Satisfaction Domain - Day 1178.0 ± 22.3974.5 ± 27.2772.8 ± 21.2282.9 ± 18.16
Effectiveness Doman - Day 1176.3 ± 21.1869.4 ± 29.1369.4 ± 29.1367.0 ± 24.80
Convenience Domain - Day 1190.1 ± 12.0386.9 ± 15.5080.9 ± 15.3190.6 ± 12.24
SecondaryMaximum Concentration (Cmax)
Time frame:
72 hours
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax)
ng/mLCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Bupivacaine566 ± 273534 ± 175742 ± 268851 ± 288
Meloxicam238 ± 96.8247 ± 89.0251 ± 104385 ± 161
SecondaryTime of Occurrence of Maximum Concentration (Tmax)
Time frame:
72 hours
Reported as:
Median · hours
Time of Occurrence of Maximum Concentration (Tmax)
hoursCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
Bupivacaine21.05 (1.07 to 49.83)20.54 (3.98 to 37.27)20.14 (2.10 to 37.02)22.48 (8.05 to 48.63)
Meloxicam47.13 (18.38 to 49.83)58.58 (23.65 to 73.28)37.17 (20.35 to 71.43)48.58 (20.85 to 73.37)

Adverse events

Collected over From the time the subject signed the informed consent form (ICF) through the Day 29 Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 and Cohort 2 (Pooled)0/66 (0%)2/66 (3%)56/66 (84.8%)
Cohort 3: Group A0/14 (0%)0/14 (0%)12/14 (85.7%)
Cohort 3: Group B0/16 (0%)0/16 (0%)14/16 (87.5%)
Cohort 40/20 (0%)2/20 (10%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
TachycardiaCardiac disorders0/660/140/161/20
HypertensionVascular disorders0/660/140/161/20
GastritisGastrointestinal disorders1/660/140/160/20
Post procedural haematomaInjury, poisoning and procedural complications1/660/140/160/20
Most frequent other events
Showing 10 of 56
Most frequent other events
EventCohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4
NauseaGastrointestinal disorders33/666/1411/166/20
VomitingGastrointestinal disorders17/663/147/165/20
ConstipationGastrointestinal disorders10/663/146/162/20
BradycardiaCardiac disorders3/663/142/160/20
Urinary retentionRenal and urinary disorders3/663/140/160/20
Oedema peripheralGeneral disorders1/663/141/160/20
Procedural painInjury, poisoning and procedural complications1/661/143/160/20
Incision site erythemaInjury, poisoning and procedural complications0/662/140/160/20
DizzinessNervous system disorders9/661/142/161/20
Anaemia postoperativeInjury, poisoning and procedural complications9/660/140/160/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
<=18 years00000
Between 18 and 65 years3566754
>=65 years318101362
Age, Continuous
Age, Continuous(years)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
Mean64.0 ± 9.6462.4 ± 8.8866.8 ± 9.8169.0 ± 8.8265.1 ± 9.64
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
Female374121265
Male29104851
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
Hispanic or Latino2013529
Not Hispanic or Latino4613131587
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American633517
White5911131598
More than one race00000
Unknown or Not Reported10001
Region of Enrollment
Region of Enrollment(participants)Cohort 1 and Cohort 2 (Pooled)Cohort 3: Group ACohort 3: Group BCohort 4Total
United States66141620116
08

Study locations

6 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Phoenix Clinical Research, LLC
    Tamarac, Florida 33321, United States
  • Midwest Clinical Research Center, LLC
    Dayton, Ohio 45417, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Plano Surgical Hospital
    Plano, Texas 75093, United States
  • Endeavor Clinical Trials, LLC.
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2020, 18 months.

Results were first posted in Aug 2023, 2 years 8 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 18 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2019
First posted
Jun 5, 2019
StartActual
Jun 5, 2019
Primary completionActual
Dec 7, 2020
CompletionActual
Jan 7, 2021
Results first posted
Aug 31, 2023
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03974932
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jun 5, 2019
Start date
Jun 5, 2019
Primary completion
Dec 7, 2020
Completion
Jan 7, 2021
Results posted
Aug 31, 2023
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion